









Markets
/
Stocks
/
nasdaq-tak
/

Takeda Pharmaceutical Co Ltd

TAK

13.440USD

+0.215+1.63%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

42.46BMarket Cap

1.28P/E TTM



Takeda Pharmaceutical Co Ltd

13.440

+0.215+1.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Takeda Pharmaceutical Co Ltd

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Takeda Pharmaceutical Co Ltd's Score

Industry at a Glance

Industry Ranking

53 / 159

Overall Ranking

149 / 4618

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.100

Target Price

+34.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Takeda Pharmaceutical Co Ltd Highlights

StrengthsRisks

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 287.84%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 287.84%.

Overvalued

The company’s latest PE is 188.63, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 78.80M shares, decreasing 1.89% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 3.71M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 8.35, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 7.40B, representing a year-over-year decrease of 8.09%, while its net profit experienced a year-over-year decrease of 30.86%.

Score

Industry at a Glance

Previous score

8.35

Change



Financials

6.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.95

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.93

Key Metrics

Free cash flow

No Data

Takeda Pharmaceutical Co Ltd's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 5.68, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 188.63, which is 0.00% below the recent high of 188.63 and 94.63% above the recent low of 10.12.

Score

Industry at a Glance

Previous score

5.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Takeda Pharmaceutical Co Ltd is 18.00, with a high of 19.30 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.100

Target Price

+34.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Takeda Pharmaceutical Co Ltd

TAK

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 7.01, which is lower than the Pharmaceuticals industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 14.44 and the support level at 12.71, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.072

Sell

RSI(14)

32.499

Neutral

STOCH(KDJ)(9,3,3)

33.045

Sell

ATR(14)

0.193

High Vlolatility

CCI(14)

-156.495

Sell

Williams %R

63.563

Sell

TRIX(12,20)

-0.245

Sell

StochRSI(14)

37.422

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

13.742

Sell

MA10

13.911

Sell

MA20

13.976

Sell

MA50

14.598

Sell

MA100

14.695

Sell

MA200

14.560

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.81. The latest institutional shareholding proportion is 2.49%, representing a quarter-over-quarter increase of 8.27%. The largest institutional shareholder is Brandes Investmen, holding a total of 3.71M shares, representing 0.12% of shares outstanding, with 22.52% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital Research Global Investors

13.30M

+0.72%

Parametric Portfolio Associates LLC

5.97M

+12.78%

Fidelity Management & Research Company LLC

4.08M

+7.23%

UBS Financial Services, Inc.

3.98M

+133.74%

Brandes Investment Partners, L.P.

Star Investors

3.71M

+5.94%

Renaissance Technologies LLC

Star Investors

3.30M

+4.48%

Aperio Group, LLC

3.20M

+21.83%

Millennium Management LLC

3.09M

+1152.21%

Goldman Sachs Asset Management, L.P.

2.85M

-1.53%

First Trust Advisors L.P.

2.60M

-5.59%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 9.49, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.21. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.